KYMR

Kymera Therapeutics, Inc.

NasdaqAdd to watchlist

Healthcare · Biotechnology

$116.33

+$3.18+2.81%

Delayed · 2026-09-16T20:00:00.000Z · marketstack

41 of 47 open-market sales on file ran under a pre-arranged trading plan ($274M), 6 did not. Who, and when

Aug 24, 2026$116.33

−$4.72−3.90%over 1M

Session

Day range76% of range

$112.88$117.43

Fundamentals

Visualize fundamentals and more

Market cap: 11.42B
P/E ratio: -

Revenue grew −16.70% in FY2025, +25.57% slower than its sector. The median across Healthcare companies this platform tracks is +8.87%.

Risk factors, year on year

Item 1AFeb 2026 10-KFeb 2025

added: 31
dropped: 34
re-drafted: 43

Out of 298 passages in this year’s Item 1A.

New this year

We focus on a limited number of research programs and product candidates. We are currently focused on our immunology portfolio, consisting of our STAT6, IRF5 and IRAK4 programs, which target key signaling pathways implicated in multiple inflammatory and …

64 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Reimbursement
Litigation
Export controls
Labour
Product recalls
Tariffs
Pandemic

And 9 more.

FDA approval
Of the large number of drugs in development in the U.S., only a small percentage will successfully complete the FDA regulatory approval process and will be commercialized, with similarly low rates of success for drugs in development in the European Union …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 16, 2026 · the last close

Kymera Therapeutics, Inc. investor relations

What KYMR has filed with the SEC. This is not Kymera Therapeutics, Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Kymera Therapeutics, Inc.

Also filed under Biotechnology, ranked by how closely they sit beside KYMR.

MRNAModerna, Inc.compare with KYMR
ROIVRoivant Sciences Ltd.compare with KYMR
VRTXVertex Pharmaceuticals Inc. / MA

XENEXenon Pharmaceuticals Inc.compare with KYMR

NVONovo Nordisk A Scompare with KYMR

Ask about Kymera Therapeutics, Inc.

The assistant answers from what KYMR has actually filed: 7 annual reports filed with the SEC, 200 Form 4 filings from the last year and 4 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from KYMR's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Kymera Therapeutics, Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Kymera Therapeutics, Inc.

Be told the moment a KYMR insider trades
Put Kymera Therapeutics, Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Kymera Therapeutics, Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Kymera Therapeutics, Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

20 more events are on Measure

Free, no card, and it does not expire. See what the paid plans add

Risk factors, year on year

Item 1AFeb 2026 10-KFeb 2025

added: 31
dropped: 34
re-drafted: 43

Out of 298 passages in this year’s Item 1A.

New this year

We focus on a limited number of research programs and product candidates. We are currently focused on our immunology portfolio, consisting of our STAT6, IRF5 and IRAK4 programs, which target key signaling pathways implicated in multiple inflammatory and …

64 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed February 2026.

FDA approval
Reimbursement
Litigation
Export controls
Labour
Product recalls
Tariffs
Pandemic

And 9 more.

FDA approval
Of the large number of drugs in development in the U.S., only a small percentage will successfully complete the FDA regulatory approval process and will be commercialized, with similarly low rates of success for drugs in development in the European Union …

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add